Placebo Effects in Neurologic Disease
- 1st Edition, Volume 153 - June 16, 2020
- Editors: Natalie P Witek, Christopher G. Goetz, Glenn Stebbins
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 1 1 1 8 - 2
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 1 1 1 9 - 9
Placebo Effects in Neurologic Disease, Volume 153, the latest release in the International Review of Neurobiology series, highlights new advances in the field, with this new vo… Read more
Placebo Effects in Neurologic Disease, Volume 153, the latest release in the International Review of Neurobiology series, highlights new advances in the field, with this new volume presenting interesting chapters on Background and Methods in Placebo, Better than Nothing: A Historical Account of Placebos and Placebo Effects from Modern to Contemporary Medicine, Determinants of PE, Strategies for Minimizing PE in Research, Maximizing placebo response in the clinic, Statistical methods for handling PE, Nocebo and Lessebo effects, Ethics of deception, Pain, Parkinson's Disease, Cognitive impairment, Epilepsy, and much more.
- Provides the authority and expertise of leading contributors from an international board of authors
- Presents the latest release in the International Review of Neurobiology series
- Updated release includes the latest information on the placebo effect
Undergraduates, graduates, academics and researchers in the field of Neurologic Disease
Part 1: Background and methods in placebo
- Better than nothing: A historical account of placebos and placebo effects from modern to contemporary medicine
- Determinants of placebo effects
- Strategies to minimize placebo effects in research investigations
- Maximizing placebo response in neurological clinical practice
- Statistical methods in handling placebo effect
- Nocebo and lessebo effects
- Deception and the ethics of placebo
- Placebo effects in pain
- Placebo responses in Parkinson's disease
- Placebo effect in subjects with cognitive impairment
- Placebo in epilepsy
Marco Annoni
Sharlet Anderson and Glenn T. Stebbins
Filipe B Rodrigues and Joaquim J Ferreira
Louise-Laure Mariani and Jean-Christophe Corvol
Rema Raman
Tiago A. Mestre
A. Jon Stoessl
Part 2: Placebo response in specific disease populations
Luana Colloca
Jau-Shin Lou
Kaori Ito and Klaus Romero
Daniel M. Goldenholz and Shira R. Goldenholz
- Edition: 1
- Volume: 153
- Published: June 16, 2020
- Language: English
NW
Natalie P Witek
Natalie Witek is at Rush Parkinson’s Disease and Movement Disorders Program, USA
Affiliations and expertise
Rush Parkinson’s Disease and Movement Disorders Program, USACG
Christopher G. Goetz
Professor and Associate Chairman, Department of Neurological Sciences, Rush University, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL
Professor of Neurological Science
Affiliations and expertise
Professor and Associate Chairman, Department of Neurological Sciences, Rush University, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL
Professor of Neurological ScienceGS
Glenn Stebbins
Glenn Stebbins is at Rush Parkinson’s Disease and Movement Disorders Program, USA
Affiliations and expertise
Rush Parkinson’s Disease and Movement Disorders Program, USARead Placebo Effects in Neurologic Disease on ScienceDirect